Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

The global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is valued at USD 18.2 Billion in 2023 and is projected to reach a value of USD 28.4 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 4.9% between 2024 and 2032. The market is driven by an aging population, rising pollution levels, the prevalence of smoking, and increasing healthcare awareness.

Key Highlights

• In 2023, North America dominated the market with 38.60% market share.
• By Drug Class, the Bronchodilators dominated the market with 32.60% market share in 2023
• Based on route of administration, the Inhalation dominated the market with 51.30% market share
• Based on distribution channel, the Wearable dominated the market with 36.20% market share

Drug Class Overview

The Drug Class Segment is divided into Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Corticosteroids, and Others. The Bronchodilators held the dominant share in 2023, accounting for significant market share of 32.60%.

The occurrence and impact of symptoms among COPD populations have led bronchodilators to become a primary therapeutic option. Both short-acting and long-acting bronchodilators are widely prescribed depending on the severity of symptoms and frequency of exacerbations. For instance, in January 2023, Airsupra (albuterol/budesonide), formerly known as PT027, was approved in the US for as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in adults with asthma. The approval by the Food and Drug Administration (FDA) was based on results from the MANDALA and DENALI Phase III trials.

Route of Administration Overview

The route of administration segment is divided into oral and inhalation. The inhalation held the dominant share in 2023, accounting for significant market share of 51.30%.

Inhaled therapies bypass the digestive system, allowing for a much quicker onset of therapeutic effects compared to oral medications. This makes inhalers ideal for delivering fast relief during COPD exacerbations characterized by acute symptoms like shortness of breath, coughing, and wheezing. For instance, in November 2023, Viatris Inc. and Theravance Biopharma announced positive results from the YUPELRI® (revefenacin) Phase III placebo-controlled clinical trial in China, assessing its efficacy and safety for COPD patients.

Regional Overview

In 2023, the North America captured 38.60% of the revenue share.

North America Chronic Obstructive Pulmonary Disease (COPD) Treatment market is driven by the presence of large pharmaceutical companies researching and developing innovative drugs and devices for COPD treatment. The region benefits from the high acceptance of new treatment options and diagnostic methods among patients and healthcare providers. This creates growth opportunities for novel molecules and combination therapies.

The US held the largest market share and is anticipated to register the highest CAGR during the forecast period. The market is driven by aging populations and high smoking rates. Additionally, the development of innovative diagnostic tools and early detection methods provides further growth opportunities. The U.S. healthcare system's focus on improving patient outcomes and the adoption of telemedicine for COPD management is contributing to market dynamics.

In Asia Pacific, Chronic Obstructive Pulmonary Disease (COPD) Treatment market is experiencing notable growth, driven by growing due to rising pollution levels, increasing smoking rates, and aging populations in the region. The expansion of healthcare infrastructure, coupled with government initiatives to improve respiratory care, is further boosting the market. Additionally, increased access to affordable medications and innovations in inhaled therapies and diagnostics are creating opportunities for growth in the Asia Pacific COPD market.

Key Trends

• Advancements in Treatment: Inhaled therapies, particularly short-acting (SABAs) and long-acting (LABAs) bronchodilators, are widely used to alleviate symptoms by relaxing the muscles around the airways
• Healthcare Infrastructure Expansion: Governments and healthcare organizations are investing in new healthcare facilities and improving existing ones to provide better access to diagnosis and treatment as the prevalence of COPD rises
• Focus on Patient-Centric Care: Personalized treatment plans that consider a patient’s specific symptoms, comorbidities, and lifestyle factors are becoming a key component of COPD management

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Increasing prevalence of COPD

COPD is a long-term respiratory disease characterized by breathing difficulties, coughing, and wheezing. It is frequently triggered by exposure to irritants such as cigarette smoke, air pollution, and dust. According to the World Health Organization (WHO), COPD ranks as the third leading cause of death worldwide. The rise in COPD prevalence is due to factors like an aging population, urbanization, and lifestyle changes, especially in developing countries with high smoking rates and significant air pollution.

Increasing collaboration in key players

Increasing collaboration among key players in the Chronic Obstructive Pulmonary Disease (COPD) Treatment market is shaping the landscape of research, development, and patient care. Pharmaceutical companies, healthcare providers, and research institutions are forming strategic partnerships to leverage their combined expertise and resources. These collaborations facilitate the sharing of knowledge and best practices, driving innovation in treatment options and enhancing the development of novel therapies. Additionally, collaborations with patient advocacy groups play a crucial role in raising awareness and understanding of COPD. By working together, key players can educate patients about the disease, its management, and available treatment options, ultimately improving health outcomes.

Competitive Landscape

The Chronic Obstructive Pulmonary Disease (COPD) Treatment market is characterized by dynamic and evolving environment with several key players and their ongoing advancement. Major Players are Astrazeneca, Alkem, Mylan N.V., Novartis AG, F.Hoffman-La Roche Ltd, Genentech Inc, Theravance Biopharma, Sunovion Pharmacuticals Inc, Sanofi, Verona Pharmaceuticals. This includes partnerships with technology firms to integrate digital health solutions, such as telemedicine and remote monitoring, into COPD management, which enhances patient engagement and adherence.

Recent Market Developments

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

• In September 2024, The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is the first biologic medicine approved in the US to treat these patients

AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of Breztri to improve cardiopulmonary outcomes in people with COPD

• In March 2024, AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled therapy Breztri/Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate, or BGF) on severe cardiopulmonary outcomes, including death, in people with chronic obstructive pulmonary disease (COPD) who also have elevated cardiopulmonary risk, irrespective of their exacerbation history

The global Chronic Obstructive Pulmonary Disease (COPD) Treatment market can be categorized as Drug Class, Route of Administration, Distribution Channel and Region.